SES
23.4.2020 08:52:11 CEST | Business Wire | Press release
SES announced today that the number of global TV households it reaches directly or indirectly via satellite has increased by 12 million to 367 million in 2019. Findings from the company’s annual Satellite Monitor market research validates, once again, SES’s position as the world’s leading video content distributor via satellite and shows the important role that satellite continues to play in reaching the largest possible audience globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200422006137/en/
Much of the increase in the 12 million TV households is attributed to the leading infrastructure of TV reception – satellite and cable – which grew by 9 million in 2019 to 153 million and 149 million homes respectively. Internet Protocol TV (IPTV) and terrestrial TV grew by a combined 3 million to 43 million and 21 million homes.
The Satellite Monitor study also showed that SES’s technical reach has increased across several continents, including Europe, Africa, Asia-Pacific (APAC), and Latin America (LATAM). Europe continues to be the strongest market for SES, with 168 million total households served by the SES fleet, up by 1 million from 2018, followed by North America at 69 million.
In LATAM, SES has captured an audience of 42 million households, a significant increase from the 34 million households reported in 2018, thanks in part to the launch of a new satellite – SES 14 – which is boosting cable and IPTV growth in the region. This year also marked the first year that SES collected results from Indonesia and the Philippines. In total, SES serves 39 million APAC households with Direct-to-Home (DTH) feeds. The research also found that SES delivers digital television to 13 million households in the Middle East and 35 million homes in Africa. Altogether, SES has observed a combined growth of almost 5 million households across APAC and Africa.
SES’s TV market research sheds light on several key trends behind the relevance of satellite broadcasting, including the transition from analog to digital TV and the rise of HD broadcast. End consumers in Ghana and Nigeria are choosing satellite TV for its better value proposition and free-to-air offerings, rather than purchasing new hardware and switching to digital terrestrial TV. The Satellite Monitor study also revealed that HD broadcast has been on the rise in Europe, with 167 million TV households, an increase of 5 million from 2018. Satellite remains the preferred choice of infrastructure when it comes to HD content broadcasting, underscoring the key value proposition of satellite broadcasting as a reliable and cost-effective video delivery to large audiences.
“Broadcasters and TV platform operators need robust and reliable data before they make the decision to enter new markets. For more than 25 years, SES has been the only satellite-based solutions provider in the world to regularly and extensively monitor the industry in specific countries and identify key trends for our customers to help them succeed in their business and expand their reach,” said Ferdinand Kayser, CEO at SES Video. “The results of our annual Satellite Monitor market research demonstrate that satellite continues to be the most optimal infrastructure to deliver high picture quality, and that despite changing consumption habits, people still strongly rely on linear TV and complement it with OTT content.”
Introduced in 1994, SES’s annual Satellite Monitor research reveals the detailed technical reach of SES and valuable insights into the video market and trends worldwide. It is seen as an important tool for SES’s customers, the leading broadcasters and content owners.
Follow us on:
Social Media
Blog
Media Library
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200422006137/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
